The Efficacy of Adductor-Canal-Block (ACB) in Patients After Knee Arthroscopy

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01254825

Enrollment

Registered

2010-12-07

Start date

2010-11-30

Completion date

2011-09-30

Last updated

2012-09-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diagnostic Knee Artroscopy, Meniscus Lesion, Minor Knee Surgery, Pain (Knee)

Keywords

Adductor Canal Block (ACB), Diagnostic Knee Arthroscopy, Saphenous nerve, Pain, Ultrasound block

Brief summary

The Purpose of this study is to determine whether Adductor-Canal-Block (ACB) is superior to placebo when it comes to analgetic efficacy after Knee-Arthroscopy.

Interventions

PROCEDUREAdductor-Canal-Block, Ropivacain

Ultrasound-guided ACB; 30 mL Ropivacain 7,5 mg/mL. Single dose.

PROCEDUREAdductor Canal Block, Placebo (saline)

Ultrasound-guided Adductor Canal Block; 30 mL Saline. Single dose.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Healthy volunteers

Yes

Inclusion criteria

* 18-80 years * Knee-arthroscopy * Written consent * ASA I-III * BMI 19-35

Exclusion criteria

* Unable to communicate in Danish * Allergic reactions toward drugs used in the trial * Pregnancy * Abuse of alcohol/drugs * Daily opioid intake * Infection at injection site * Can not be mobilised to 5 meters of walk; pre-surgery

Design outcomes

Primary

Measure	Time frame	Description
Pain-Score (VAS) - patient standing	2 hours postoperative	Pain-score messured on a Visual Analog Scale (VAS) 2 hours after adductor canal block. Patient standing. Intervention-group vs. placebo-group.

Secondary

Measure	Time frame	Description
Pain-score (VAS), patient standing	1,2,4,6,8,24 hours postoperative	ACB-group vs. placebo
Pain-score (VAS), after 5 meters of walk	2,4,6,8,24 hours postoperative	ACB-group vs. placebo
Total Opioid-consumption	0-24 hours postoperative	ACB-group vs. placebo-group
Pain-score (VAS), patient at rest	0,1,2,4,6,8,24 hours postoperative	ACB-group vs. placebo
Postoperative Nausea and vomiting	0-1, 1-2, 2-4, 4-6, 6-8, 8-24 hours postoperative	Rating-scale 0-3 ACB-group vs. placebo-group
Postoperative ondansetron consumption	In-hospital	ACB-group vs. placebo-group
Sedation	0,1,2,4,6,8,24 hours postoperative	Rating-scale: 0-3 ACB-group vs. placebo-group
Opioid-consumption, postoperative	0-2, 2-4, 4-6, 6-8, 8-24 hours postoperative	i.v. morfin 0-2 hours postoperative tbl. morfin 2-24 hours postoperative ACB vs. placebo

Countries

Denmark

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 10, 2026